Timothy E Wilens, MD

Robert L. Findling, MD, MBA; and Timothy Wilens, MD, share advice on the treatment of pediatric ADHD and new agents in the pipeline.

Drs Robert L. Findling and Timothy Wilens discuss the efficacy and safety data of serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) in childhood ADHD.

Robert L. Findling, MD, MBA, and Timothy Wilens, MD, review serdexmethylphenidate-dexmethylphenidate, a combination agent recently approved for the treatment of ADHD.

Robert L. Findling, MD, MBA, and Timothy Wilens, MD, consider the dosing and adherence challenges that arise in pediatric ADHD, as well as the potential benefits and damages of patients taking a break from treatment.

Experts in psychiatry discuss strategies for titrating to optimal doses for patients with pediatric ADHD.

Robert L. Findling, MD, MBA, and Timothy Wilens, MD, provide an overview of available treatment options for patients with pediatric ADHD.

Experts in psychiatry review the differences between pharmacological therapy and nonpharmacological therapy as well as the criteria to start a patient on medication.

Robert L. Findling, MD, MBA, and Timothy Wilens, MD, share their thoughts on treatment considerations with the patient’s family in pediatric ADHD.

Experts in psychiatry discuss the impact of childhood ADHD on self-esteem, at home, and academically.

Robert L. Findling, MD, MBA, and Timothy Wilens, MD, review specific risk factors of pediatric ADHD, focusing on family history.

Robert L. Findling, MD, MBA, and Timothy Wilens, MD, discuss the prevalence of pediatric ADHD and how diagnosis has spiked in recent years.

Adolescents evolve from child to young adult without the maturity of adulthood to help them navigate the transition, particularly when it comes to the perils of substance use and addiction. Pediatricians who care for transitional-aged youth with substance use disorders have new paradigms that have shown promise for treating addiction and its accompanying comorbidities and for sustaining recovery over time.